NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital

CompletedN/A

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions: Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease, Uveitis

Interventions: Switch from REMICADE® to INFLECTRA®

Countries: France

The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic, gastro-enterologic or ophthalmic condition

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female over 18 year old
* Patient treated with REMICADE® in Cochin hospital
* More than 3 perfusions of REMICADE® before the switch to INFLECTRA®

Exclusion Criteria:

* none

Locations (1)

Paris, Paris, France